Last reviewed · How we verify
Eye injection (Mydrane)
Eye injection (Mydrane) is a Ophthalmic combination agent (mydriatic + anesthetic) Small molecule drug developed by Medical University of Graz. It is currently FDA-approved for Mydriasis and anesthesia during cataract surgery. Also known as: Mydrane.
Mydrane is a combination ophthalmic injection that dilates the pupil and provides anesthesia for cataract surgery by combining mydriatic and anesthetic agents.
Mydrane is a combination ophthalmic injection that dilates the pupil and provides anesthesia for cataract surgery by combining mydriatic and anesthetic agents. Used for Mydriasis and anesthesia during cataract surgery.
At a glance
| Generic name | Eye injection (Mydrane) |
|---|---|
| Also known as | Mydrane |
| Sponsor | Medical University of Graz |
| Drug class | Ophthalmic combination agent (mydriatic + anesthetic) |
| Target | Muscarinic acetylcholine receptors (tropicamide); alpha-1 adrenergic receptors (phenylephrine); sodium channels (lidocaine) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Mydrane contains tropicamide (anticholinergic mydriatic), phenylephrine (alpha-1 adrenergic agonist), and lidocaine (local anesthetic). The combination produces rapid pupil dilation and corneal anesthesia without requiring separate injections, improving surgical efficiency and patient comfort during cataract procedures.
Approved indications
- Mydriasis and anesthesia during cataract surgery
Common side effects
- Transient corneal edema
- Increased intraocular pressure
- Conjunctival injection
- Mydriasis-related visual disturbance
Key clinical trials
- Efficacy Mydrane ® for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma. (NA)
- Comparison Mydriasis by Mydrane With Topical Drop Application (PHASE4)
- Effect of Intracameral Injection of Mydriatic Plus Anaesthetic Combination on Corneal Endothelial Count in Phaco (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eye injection (Mydrane) CI brief — competitive landscape report
- Eye injection (Mydrane) updates RSS · CI watch RSS
- Medical University of Graz portfolio CI
Frequently asked questions about Eye injection (Mydrane)
What is Eye injection (Mydrane)?
How does Eye injection (Mydrane) work?
What is Eye injection (Mydrane) used for?
Who makes Eye injection (Mydrane)?
Is Eye injection (Mydrane) also known as anything else?
What drug class is Eye injection (Mydrane) in?
What development phase is Eye injection (Mydrane) in?
What are the side effects of Eye injection (Mydrane)?
What does Eye injection (Mydrane) target?
Related
- Drug class: All Ophthalmic combination agent (mydriatic + anesthetic) drugs
- Target: All drugs targeting Muscarinic acetylcholine receptors (tropicamide); alpha-1 adrenergic receptors (phenylephrine); sodium channels (lidocaine)
- Manufacturer: Medical University of Graz — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Mydriasis and anesthesia during cataract surgery
- Also known as: Mydrane
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing